SG/CALL/MODERNA/200/0.1/20.09.24 | Delayed Deutsche Boerse AG 11:36:59 2024-05-10 EDT | ||
| 0.099 EUR | -23.85% |
|
| Current month | +8.33% | ||
| 1 month | -13.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.099 | -23.85% | 0 |
| 24-05-09 | 0.13 | +8.33% | 0 |
| 24-05-08 | 0.12 | 0.00% | 0 |
| 24-05-07 | 0.12 | -14.29% | 0 |
| 24-05-06 | 0.14 | -22.22% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 10, 2024 at 11:36 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SQ80AW |
| ISIN | DE000SQ80AW9 |
| Date issued | 2023-02-13 |
| Strike | 200 $ |
| Maturity | 2024-09-20 (133 Days) |
| Parity | 10 : 1 |
| Emission price | 3.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.14 € |
|---|---|
| Lowest since issue | 0.058 € |
| Spread | 0.014 € |
| Spread % | 12.73% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
122.7
USD
Average target price
139.4
USD
Spread / Average Target
+13.58%
- Stock Market
- Warrants
- Warrant